Navigation Links
Beckman Coulter Announces Second Quarter 2008 Results
Date:7/25/2008

(0.4)

Net cash used in financing activities (6.7) (52.5)

Effect of exchange rates on cash and cash

equivalents 4.0 0.6

Change in cash and cash equivalents (13.5) (13.2)

Cash and cash equivalents-beginning of period 83.0 75.2

Cash and cash equivalents-end of period $69.5 $62.0

BECKMAN COULTER, INC

REVENUE BY SEGMENT

(in millions)

(unaudited)

Three Months Ended

June 30, Constant

Reported Currency

2008 2007 Growth % Growth % *

Clinical Diagnostics

Chemistry and Clinical

Automation $233.0 $205.0 13.7% 9.4%

Cellular 244.5 208.3 17.4% 13.0%

Immunoassay and

Molecular Diagnostics 193.3 159.7 21.0% 16.3%

Total Clinical

Diagnostics 670.8 573.0 17.1% 12.6%

Life Sciences 127.5 116.7 9.3% 4.3%

Total revenue $798.3 $689.7 15.7% 11.2%

Six Months Ended

June 30, Constant

Reported Currency

2008 2007 Growth % Growth % *

Clinical Diagnostics

Chemistry and Clinical

Automation $448.6 $389.0 15.3% 11.0%

Cellular 476.0 402.7
'/>"/>

SOURCE Beckman Coulter, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Beckman Coulter Announces Second Quarter 2008 Earnings to be Released on Friday, July 25, 2008, Before Market Opens
2. Upcoming Beckman Coulter Investor Events Second Half of 2008
3. Beckman Coulter to Present at Upcoming Healthcare Conferences
4. Beckman Coulter Announces First Quarter 2008 Results
5. Beckman Coulter Acquires Rights to Hepatitis C Virus
6. Beckman Coulter Declares Quarterly Dividend Payout of $0.17 Per Share
7. The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory
8. Beckman Coulter to Present at the 2008 Bear Stearns London Healthcare Conference
9. Beckman Coulter Releases the High-Volume UniCel(R) DxC 880i Integrated Work Cell
10. AcroMetrix Signs Development and Supply Agreement With Beckman Coulter Inc. for Molecular Quality Control Standards
11. Beckman Coulter to Present at the JPMorgan Healthcare Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...ador to also Visit Detroit , ...ppia, French Ambassador for International Investme...gency, , , , ,What: Ambassador Appia is available... initiatives adopted by France to further develop ...nnovation and development., , ,When: Available for...
(Date:11/24/2009)...re-FirstCall/--Sigma-AldrichCorporation(Nasdaq: SI...day,December1stat1:45PMGMTinLondon,7:45AMUS/CST.In...heInternetavailableat http://inve s tor.sig m ...toaccessthisfile. ,, AboutSigma-Aldrich: Sig...mpany.Itschemicalandbiochemicalproductsandkitsareu...
(Date:11/24/2009)...re-Asia/--ShanghaiBiolaxyannouncedthe,ChineseState...vestigationalnewdrugapplication(IND)foritsoralinsu...totreatdiabetes.ThisIND,approvalallowsBiolaxytoini...sadisordercharacteristicofhighbloodglucoseandpoor,...severemicro-and,macro-vasculardiseases,lossofvisio...
(Date:11/24/2009)...wire-FirstCall/--Shireplc(LSE:SHP,NASDAQ: SHPGY )...announcedthatithassubmittedaMAAtotheEuropeanMedici...eplacementtherapyindevelopment,forthetreatmentofTy...ionforvelaglucerasealfathathasbeensubmitted,withpr..., Basedonaglobalsupplyshortageofthecurrentlyappro...
Breaking Biology Technology:Biolaxy Secures IND Approval for Oral Insulin 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3
...therlands, January 22 Progentix,Orthobiology B.V....cing,Round. The round was led by BioGeneration Ven...ed in 2007 and develops a,unique suite of osteoind...in bone regenerative surgery. Progentix bone graft...iomaterial scaffolds that have the ability to,attr...
... Jan. 21 VNUS(R) Medical,Technologies, Inc. (Nasd...,for the minimally invasive treatment of periphera...o report its financial results for the,fourth quar...rket on,February 7., VNUS plans to host its regul... p.m. ET on February 7. This call will be webcast ...
...mbines first approved direct renin inhibitor with ... a single tablet - Data show combination of Tektu...blood pressure reductions compared to either drug ... most require two or more, medicines - single-ta... number of pills patients take, ...
Other Biology Technology:Progentix Orthobiology B.V. Closes Series A Financing Round 2VNUS Medical Technologies to Report Fourth-Quarter 2007 Results and Webcast Teleconference on February 7 2Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure 2Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure 3Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure 4Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure 5
(Date:11/26/2009)...itehead researchers have developed a new type of g... genes and proteins used by pathogens, according t... cultures genes are present in two copies: one inh...ne inactivation by mutation is therefore inefficie...d copy usually remains active and takes over. , ...
(Date:11/25/2009)...ch, may be used to boost resistance to, or slow, t... of Medicine researchers report in a study publish...ce . , Parkinson,s disease is caused by a degene...ain known as the substantia nigra, which is respon... of dopamine in late-stage Parkinson,s causes symp...
(Date:11/25/2009)...the linchpin of the environment, where atmosphere,...ny students see soil as "just dirt" a place to gr...s are challenged with the task of helping students...of soil in the environment. , A collaborative p...at University of Nebraska-Lincoln, Oregon State Un...
Breaking Biology News(10 mins):Knockouts in human cells point to pathogenic targets 2Hormone ghrelin can boost resistance to Parkinson's disease 2It's not just dirt! 2For peats sake 3A Alternative growing media 9796 1For peats sake 3A Alternative growing media 9796 2Blue Cross Blue Shield of Georgia Offers The Healing Book to Help Young Life Insurance Beneficiaries Cope with Losing a Loved One 56276 1Blue Cross Blue Shield of Georgia Offers The Healing Book to Help Young Life Insurance Beneficiaries Cope with Losing a Loved One 56276 2Fruit Even Healthier Than Thought 3A Study 56271 1
...atory birds choose the nesting location of their f...ry in the bird world. But a new University of Mar...suggests that the environmental conditions the bir...re they breed for the rest of their lives, a facto...s climate change makes their winter habitats hotte...
...EBRUARY 11, 2008 -- Transgenic cotton cultivars we...007. Transgenic cultivars with pest-managing trait... lint and seed, while the expressed propriety trai.../or enable use of broad-spectrum herbicides for we...reasing number of cultivars and an increasingly di...
...st strips buffering rivers and streams of the Amaz...he current legal requirement, according to pioneer...f East Anglia (UEA). , Published in the journal C... wildlife study in remnant riparian tropical fores...rently requires that all forest strips alongside r...
Other Biology News:Early environment may be key to determining bird migration location 2Early environment may be key to determining bird migration location 3Is transgenic cotton more profitable? 2Amazon corridors far too narrow, warn scientists 2
Normal Chicken Serum from Equitech-Bio
Pig Serum Non-Sterile Trace-Hemolyzed from Pel-Freez Biologicals
Mouse Anti-Keap1 Monoclonal Antibody, Unconjugated, Clone 333116 from R&D Systems
Normal Guinea Pig Serum from Equitech-Bio
Biology Products: